Ascletis Pharma Inc.

OTCPK:ASCL.F Stock Report

Market Cap: US$2.0b

Ascletis Pharma Management

Management criteria checks 2/4

Ascletis Pharma's CEO is Jason Wu, appointed in Apr 2013, has a tenure of 13.08 years. total yearly compensation is CN¥102.22M, comprised of 43.6% salary and 56.4% bonuses, including company stock and options. directly owns 46.36% of the company’s shares, worth $932.61M. The average tenure of the management team and the board of directors is 6.9 years and 8.1 years respectively.

Key information

Jason Wu

Chief executive officer

CN¥102.2m

Total compensation

CEO salary percentage43.63%
CEO tenure13.1yrs
CEO ownership46.4%
Management average tenure6.9yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jason Wu's remuneration changed compared to Ascletis Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025CN¥102mCN¥45m

-CN¥360m

Sep 30 2025n/an/a

-CN¥309m

Jun 30 2025n/an/a

-CN¥259m

Mar 31 2025n/an/a

-CN¥280m

Dec 31 2024CN¥55mCN¥39m

-CN¥301m

Sep 30 2024n/an/a

-CN¥280m

Jun 30 2024n/an/a

-CN¥258m

Mar 31 2024n/an/a

-CN¥202m

Dec 31 2023CN¥58mCN¥58m

-CN¥145m

Sep 30 2023n/an/a

-CN¥194m

Jun 30 2023n/an/a

-CN¥243m

Mar 31 2023n/an/a

-CN¥279m

Dec 31 2022CN¥23mCN¥22m

-CN¥315m

Sep 30 2022n/an/a

-CN¥246m

Jun 30 2022n/an/a

-CN¥176m

Mar 31 2022n/an/a

-CN¥188m

Dec 31 2021CN¥20mCN¥20m

-CN¥199m

Sep 30 2021n/an/a

-CN¥234m

Jun 30 2021n/an/a

-CN¥269m

Mar 31 2021n/an/a

-CN¥239m

Dec 31 2020CN¥11mCN¥11m

-CN¥209m

Sep 30 2020n/an/a

-CN¥155m

Jun 30 2020n/an/a

-CN¥100m

Mar 31 2020n/an/a

-CN¥98m

Dec 31 2019CN¥11mCN¥11m

-CN¥96m

Compensation vs Market: Jason's total compensation ($USD15.03M) is above average for companies of similar size in the US market ($USD5.53M).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.

CEO

Jason Wu (61 yo)

13.1yrs
Tenure
CN¥102,218,000
Compensation

Dr. Jinzi Wu, also known as Jason, Ph D, is a Founder of Ascletis Pharma Inc and has been its Chairman since March 30, 2018 and has been its CEO since April 2013. In 2013, Dr. Wu founded Ascletis BioScienc...

Leadership Team

NamePositionTenureCompensationOwnership
Jinzi Wu
Founder13.1yrsCN¥102.22m46.36%
$ 932.6m
Hejingdao Wu
Senior VP of Operations & Executive Director5.2yrsCN¥6.38m0.11%
$ 2.2m
Kristjan Gudmundsson
Senior Consultant & Head of Discovery13yrsno datano data
George Hill
Senior Consultant & Chief Medical Advisor8.7yrsno datano data
John Gargiulo
Chief Business Officer4yrsno datano data
Ming Fai Chung
Company Secretary3.8yrsno datano data
6.9yrs
Average Tenure
59yo
Average Age

Experienced Management: ASCL.F's management team is seasoned and experienced (6.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jinzi Wu
Founder12.3yrsCN¥102.22m46.36%
$ 932.6m
Hejingdao Wu
Senior VP of Operations & Executive Director8.2yrsCN¥6.38m0.11%
$ 2.2m
Jiong Gu
Independent Non-Executive Director8.1yrsCN¥397.00kno data
Yizhen Wei
Independent Non-Executive Director8.1yrsCN¥397.00kno data
Lin Hua
Independent Non-Executive Director8.1yrsCN¥397.00kno data
8.1yrs
Average Tenure
51yo
Average Age

Experienced Board: ASCL.F's board of directors are considered experienced (8.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 08:14
End of Day Share Price 2026/05/19 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ascletis Pharma Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangChina Merchants Securities (HK) Co., Ltd
Wangbin ZhouCitigroup Inc
Ming JiangEast Asia Qianhai Securities Co., Ltd